Form 8-K - Current report:
SEC Accession No. 0001689375-24-000014
Filing Date
2024-03-13
Accepted
2024-03-13 07:08:10
Documents
16
Period of Report
2024-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trda-20240313.htm   iXBRL 8-K 28878
2 EX-99.1 entrada_q42023earningsrele.htm EX-99.1 56362
6 GRAPHIC image_0a.jpg GRAPHIC 30141
  Complete submission text file 0001689375-24-000014.txt   266660

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trda-20240313.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trda-20240313_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trda-20240313_pre.xml EX-101.PRE 13585
17 EXTRACTED XBRL INSTANCE DOCUMENT trda-20240313_htm.xml XML 2928
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40969 | Film No.: 24744558
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)